EMD SERONO

Laura Matz of Merck KGaA introduced M-TrustTM, a cyber-physical trust platform enhancing product traceability and authenticity through digitalization. Utilizing Web 3.0, it creates digital twins for security and digitizes quality control, integrating crypto anchors for traceability and smart contracts for automation. Launched in beta, it aims to adapt to evolving tech and regulations, showcased at CES 2025.

M-Trust™, launched by Merck KGaA, is a secure cyber-physical trust platform enhancing product quality and authenticity through digital twins. Unveiled at CES 2025, it uses Web 3.0 technology for traceability and quality control, integrating crypto anchors and smart contracts. Available in beta globally.

Urothelial carcinoma (UC) subtypes, including sarcomatoid UC and squamous cell carcinoma, present treatment challenges due to limited data. Clinical trials and biomarker testing are crucial for effective management. Rare subtypes are likely underreported, emphasizing the need for second pathology opinions and inclusive trial designs.

Bionxt Solutions plans to launch a pilot clinical trial in H2 2025 comparing BNT23001, a sublingual cladribine formulation, to Mavenclad for MS treatment. The sublingual film aims to ease administration for patients with swallowing difficulties and is expected to act faster. Bionxt is working with a manufacturing partner and plans to file for clinical trial approval in Europe by mid-2025. Preclinical studies showed BNT23001 has comparable pharmacological properties to Mavenclad.

The non-small cell lung cancer market is driven by increasing NSCLC cases, uptake of immune checkpoint inhibitors, emerging premium therapies, and awareness of mutations. DelveInsight's report covers current treatment practices, emerging drugs, market share, and forecasted market size from 2019 to 2032 in 7MM. Key companies and therapies include EMD Serono, Merck, AstraZeneca, Bristol-Myers Squibb, and therapies like M1774, C-TIL051, and Osimertinib. FDA approvals for Opdivo and Tagrisso in 2024 highlight advancements in treatment.

E. Heath reports advisory/consulting, steering committee, honoraria/paid travel, speaker’s bureau, and research support from various companies. J.R. Ribeiro, K. Poorman, and J. Xiu report personal fees and other support from Caris Life Sciences. H. Mamdani reports other support and grants from Daiichi Sankyo, AstraZeneca, and Genentech. A.F. Shields reports personal fees from Caris Life Sciences. G.L. Lopes reports stock ownership, honoraria, consulting, research funding, travel, and other relationships with multiple companies. S.A. Kareff reports personal fees and travel grants from various organizations. M. Radovich and G.W. Sledge report other support from Caris Life Sciences. G.A. Vidal reports relationships with Guardant360, Gilead, BillionToOne, Genentech/Roche, GSK, and AstraZeneca. J.L. Marshall reports personal fees from Caris. No other disclosures were reported by the other authors.

De-escalation strategies for HPV-positive oropharyngeal cancer failed to show noninferiority compared to standard care, resetting the bar for future trials. Standard treatment with 70 Gy RT plus cisplatin achieved 98.1% 2-year PFS, while de-escalated strategies with 60 Gy RT plus cisplatin or nivolumab yielded 88.6% and 90.3% PFS, respectively. Future de-intensification studies must be more selective and effective.

S.B., A.D., T.J.F., I.M.G., L.G., R.K.J., G.K., J.M.L., G.V.L., K.P.-J., H.I.S., J.T., R.R.W., M.W., Y.L.W. have disclosed various financial interests, including funding, advisory roles, patents, and equity. C.M.B., E.B., M.W.B., and K.P. declare no competing interests.

S.K., D.A.M., J.P., H.S., X.Z., P.H., T.X., and H.S. have financial ties to various pharmaceutical companies, including stock ownership and advisory roles. F.C., J.D., E.V.C., H.S.W., T.Y., R.Y., and J.T. also report consulting or advisory roles and research funding from multiple institutions and companies.